Abstract
Glaucoma is the leading cause of irreversible blindness and is characterized by progressive retinal ganglion cell (RGC) degeneration. Hydrogen sulfide (H2S) is a potent neurotransmitter and has been proven to protect RGCs against glaucomatous injury in vitro and in vivo. This study is to provide an overall insight of H2S’s role in glaucoma pathophysiology. Ischemia-reperfusion injury (I/R) was induced in Sprague-Dawley rats (n = 12) by elevating intraocular pressure to 55 mmHg for 60 min. Six of the animals received intravitreal injection of H2S precursor prior to the procedure and the retina was harvested 24 h later. Contralateral eyes were assigned as control. RGCs were quantified and compared within the groups. Retinal proteins were analyzed via label-free mass spectrometry based quantitative proteomics approach. The pathways of the differentially expressed proteins were identified by ingenuity pathway analysis (IPA). H2S significantly improved RGC survival against I/R in vivo (p < 0.001). In total 1115 proteins were identified, 18 key proteins were significantly differentially expressed due to I/R and restored by H2S. Another 11 proteins were differentially expressed following H2S. IPA revealed a significant H2S-mediated activation of pathways related to mitochondrial function, iron homeostasis and vasodilation. This study provides first evidence of the complex role that H2S plays in protecting RGC against I/R.
Keywords: hydrogen sulfide, glaucoma, neuronal apoptosis, label-free mass spectrometry, mitochondrial function, signalling pathways
1. Introduction
Glaucoma is one of the leading causes of irreversible blindness worldwide [1] and is characterized by progressive optic nerve and retinal ganglion cell (RGC) degeneration [2]. Although elevated intraocular pressure (IOP) is the main risk factor and mainstay of treatment, simply lowering IOP may fail to halt the disease progression in many patients despite delaying RGC death. Novel strategies which halt RGC loss are desperately needed to prolong visual function in glaucoma [3].
Along with carbon monoxide (CO) and nitric oxide (NO), hydrogen sulfide (H2S), has been recognized as a third endogenous gaseous signaling molecule [4]. The importance of NO in biology and medicine was highlighted in 1998 when the Nobel Prize was awarded in Physiology and Medicine to Robert Furchgott, Louis Ignarro and Ferid Murad for their pioneering work on the role of NO in the nervous, cardiovascular and immune systems [5]. In the same time period, CO has also been recognized as putative neurotransmitters [6]. They are both involved in several important aspects of neuronal function. In physiological condition, NO formed in the eye is beneficial in preventing the genesis of glaucoma or halting its progress; however, excessive NO would become pathogenic in the progress of glaucomatous optic neuropathy [7]. In vitro and in vivo studies have shown evidence of NO’s involvement in retinal degeneration, the regulation of IOP and the production of aqueous humor [8,9,10]. Drugs inhibiting NO formation showed protective effects in the retina against elevated IOP in glaucoma animal models [11,12,13]. On the other hand, The CO production system in the retina has been highlighted as a protective mechanism, its protecting role is demonstrated in the regulation of Ischemia-reperfusion (I/R) -induced damage, protecting retinal ganglion cells against oxidative damage, increases retinal and choroidal blood flows and downregulating inflammatory response in the anterior segment of the eye [14,15,16]. Only recently, has H2S been recognized as a physiological gasotransmitter of comparable importance to NO and CO [17]. It is produced via cysteine catabolism by the cytoplasmic enzymes, cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE), and also via 3-mercaptopyruvate catabolism by 3-mercaptopyruvate sulfurtransferase (3-MST) [18]. H2S has recently been considered an endogenous gasotransmitter with protective potential at low concentrations. Alteration of endogenous H2S levels in the retina is also linked to different pathological conditions, and its exogenous donors have been shown to exhibit potential in protecting retinal ganglion cells against insults such as diabetic retinopathy, ischemia-reperfusion injury and N-methyl-D-aspartic acid (NMDA)-induced excitatory neurotoxicity [16,19,20]. We showed in our previous study that endogenous H2S synthesis via 3-MST is increased in a glaucoma animal model after seven weeks of IOP elevation. Furthermore, we documented that GYY4137, a slow-release H2S donor, effectively protected RGC against different glaucomatous injuries in vitro and in vivo, in a dose-dependent manner [21].
The neuroprotective effect of H2S was partly attributed to its capability of vasorelaxation, anti-oxidative stress, neuroendocrine regulation and inflammation suppression [22,23,24], but our current understanding of the mechanism behind RGC apoptosis and protective properties of H2S is far from comprehensive.
In this study we examined the potential protective mechanisms activated by H2S in a glaucoma animal model. In this work, we used mass spectrometry-based proteomics to elucidate how protein expression changes at the cellular level, in H2S-treated and H2S-untreated retinae of Sprague-Dawley rats that underwent acute elevated IOP (ischemia-reperfusion injury), and to provide a more precise direction for further studies.
2. Results
2.1. Pretreatment of H2S Improves RGC Survival against Ischemia-Reperfusion Injury
IOP of the animals was elevated to 55 mmHg for 60 min to induce regional ischemic injury, followed by 24 h of reperfusion. I/R injury resulted in significant reduction in the number of RGC in the operated eyes (1101.7 ± 116.4 RGC/mm2) compared to the contralateral control (1310.6 ± 236.4 RGC/mm2). While injection of the H2S precursor, GYY4137, prior to I/R injury significantly improved RGC survival (1295.4 ± 136.1 RGC/mm2). Total number of RGC between control and H2S treated group is not significantly different (Figure 1) (*** p < 0.001, ** p < 0.01, n = 6 per group, means ± SD).
2.2. Proteomic Profiling
MS-based discovery proteomics was used to identify and distinguish proteome profiles of rat retina undergoing I/R injury with or without pre-treatment of H2S. In total 1115 retinal proteins were identified with a false discovery rate (FDR) of 1% (the complete list of proteins can be found as Supplementary Data S1 “Total proteins”). Ischemia/reperfusion injury with (1046 proteins) or without H2S pretreatment (1015 proteins) resulted in the expression of a slightly lower number of proteins than the control group (CTRL; 1070 proteins). All three groups showed an overlap of 963 proteins (Figure 2B). Furthermore, 34 proteins were exclusively expressed in the control, 14 proteins in I/R group and H2S group.
2.3. Differential Expression of Retinal Proteins between I/R and H2S Groups
A total number of 79 proteins were found to be significantly differentially expressed (p < 0.05) in the retinal samples of both I/R and H2S groups compared to the control group. A slightly higher correlation was observed between the H2S vs. CTRL group compared with I/R vs. CTRL group, which indicates high similarities between the proteome of control and H2S pre-treated groups. A heat map with unsupervised hierarchical clustering of retina proteome in I/R, H2S and CTRL groups shows the segregation of identified proteins into various clusters (Figure 2C, also can be found in Supplementary Data S2).
Forty-eight proteins were found to be differentially expressed (p < 0.05) in the retina samples of the I/R group compared to the CTRL group (listed in Table 1, also see Figure 3A). The five most significantly down-regulated proteins are 116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2), E3 ubiquitin-protein ligase NEDD4 (Nedd4), adenylyl cyclase-associated protein 1 (CAP1), mucin-19 (MUC19) and hydroxymethylglutaryl-CoA lyase, mitochondrial (Hmgcl). The five most significantly up-regulated proteins are vesicular inhibitory amino acid transporter(SLC32A1), inorganic pyrophosphatase (PPA1), AP-2 complex subunit mu (AP2M1), mannose-P-dolichol utilization defect 1 protein (MPDU1) and NADH-cytochrome b5 reductase 3(Cyb5r3).
Table 1.
Protein IDs | Gene Names | p-Value | Abundance |
---|---|---|---|
Q15029 | EFTUD2 | 0.0006042 | low |
Q62940 | Nedd4 | 0.00061229 | low |
Q08163 | Cap1 | 0.00086462 | low |
Q7Z5P9 | MUC19 | 0.00091244 | low |
Q9H598 | SLC32A1 | 0.00091751 | high |
Q15181 | PPA1 | 0.0016681 | high |
Q3ZCM7 | TUBB8 | 0.0031885 | low |
Q96CW1 | AP2M1 | 0.00352499 | high |
O75352 | MPDU1 | 0.00377415 | high |
P97519 | Hmgcl | 0.00470492 | low |
P34931 | HSPA1L | 0.00595437 | low |
P20070 | Cyb5r3 | 0.00814946 | high |
P36871 | PGM1 | 0.00912329 | high |
B0BNE5 | Esd | 0.0096494 | high |
Q9UNM6 | PSMD13 | 0.0112771 | high |
Q5XIK2 | Tmx2 | 0.0124046 | high |
P46844 | BLVRA | 0.0135271 | high |
Q63524 | Tmed2 | 0.0150562 | high |
Q63598 | Pls3 | 0.0158343 | low |
Q62927 | Cnga1 | 0.0175332 | low |
Q8IX01 | SUGP2 | 0.019042 | low |
P97612 | Faah | 0.0195873 | low |
P61203 | Cops2 | 0.0208293 | high |
Q497B0 | Nit2 | 0.0211131 | high |
P39069 | Ak1 | 0.0216897 | high |
P11506 | Atp2b2 | 0.0227347 | low |
Q7TP47 | Syncrip | 0.0239965 | low |
Q8NCB2 | CAMKV | 0.0247766 | low |
P14854 | COX6B1 | 0.0270203 | low |
P11167 | Slc2a1 | 0.0276784 | low |
P45479 | Ppt1 | 0.0279009 | high |
Q9QZA2 | Pdcd6ip | 0.0299058 | low |
P41498 | Acp1 | 0.032686 | high |
P10155 | TROVE2 | 0.0333496 | high |
Q64428 | Hadha | 0.0337918 | low |
P83916 | CBX1 | 0.0342579 | high |
Q64560 | Tpp2 | 0.0352463 | high |
P26453 | Bsg | 0.0366156 | high |
Q641X8 | Eif3e | 0.0387402 | high |
Q6AYR6 | Hdhd2 | 0.0399141 | high |
P08413 | Camk2b | 0.0416695 | high |
O08838 | Amph | 0.0425382 | low |
Q86V81 | ALYREF | 0.0427918 | high |
P63211 | GNGT1 | 0.043069 | low |
P84090 | ERH | 0.0437723 | low |
P41542 | Uso1 | 0.0456321 | low |
Q3ZAQ7 | VMA21 | 0.0494713 | low |
P85973 | Pnp | 0.0496038 | high |
Closer examination of the protein levels within each of the dominant clusters showed two major clusters of proteins that were involved in the mechanism underlying the neuroprotective properties of H2S against I/R.
First, among 48 proteins, which were differentially expressed in the retina samples of I/R group compared to CTRL group, a cluster of 18 proteins can be restored to near normal or normal level by H2S pretreatment, which comprised 22.78% of the total differentially expressed proteins due to I/R injury (Table 2, Figure 3B,C). Proteins were classified by PANTHER classification system into six categories, which are cytoskeletal protein, membrane traffic protein, metabolite interconversion enzyme, nucleic acid binding protein, protein modifying enzyme and translational protein.
Table 2.
Protein Class | Gene Name | p-Value | Abundance |
---|---|---|---|
Cytoskeletal Protein | TUBB8 | 0.0031885 | low |
Membrane Traffic Protein | AP2M1 | 0.00352499 | high |
Tmed2 | 0.0150562 | high | |
Metabolite Interconversion Enzyme | Hmgcl | 0.00470492 | low |
Nit2 | 0.0211131 | high | |
Hadha | 0.0337918 | low | |
Nucleic Acid Binding Protein | SUGP2 | 0.019042 | low |
Syncrip | 0.0239965 | low | |
Protein Modifying Enzyme | PSMD13 | 0.0112771 | high |
CAMKV | 0.0247766 | low | |
Tpp2 | 0.0352463 | high | |
Translational Protein | EFTUD2 | 0.0006042 | low |
Eif3e | 0.0387402 | high | |
Other Protein | SLC32A1 | 0.00091751 | high |
MPDU1 | 0.00377415 | high | |
Cyb5r3 | 0.00814946 | high | |
Tmx2 | 0.0124046 | high | |
Slc2a1 | 0.0276784 | low |
The five proteins, which are most significantly up-regulated by H2S pretreatment compared to I/R group, are CaM kinase-like vesicle-associated protein (CAMKV), trifunctional enzyme subunit alpha (Hadha), solute carrier family 2, facilitated glucose transporter member 1(Slc2a1), Hmgcl and SURP and G-patch domain-containing protein 2 (SUGP2). Furthermore, the proteins that were significantly down-regulated by H2S, included mannose-P-dolichol utilization defect 1 protein (MPDU1), tripeptidyl-peptidase 2 (Tpp2), NADH-cytochrome b5 reductase 3(Cyb5r3), eukaryotic translation initiation factor 3 subunit E (Eif3e) and 26S proteasome non-ATPase regulatory subunit 13 (PSMD13).
The second cluster was characterized by the expression of certain proteins, which were only differentially expressed due to pre-treatment of H2S (Table 3, Figure 3D–E). Proteins were classified by PANTHER classification system into five categories, calcium-binding protein, cytoskeletal protein, metabolite interconversion enzyme, nucleic acid binding protein and translational protein. Pre-treatment of H2S significantly increased the abundance of glutaredoxin-3(Glrx3), dynein light chain roadblock-type 1(Dynlrb1) and probable ATP-dependent RNA helicase DDX5(DDX5), and significantly decreased the abundance of small nuclear ribonucleoprotein G(SNRPG), annexin A6(Anxa6) and keratin, type II cytoskeletal 1(KRT1).
Table 3.
Protein Class | Gene Name | p-Value | Abundance |
---|---|---|---|
Calcium-binding Protein | Anxa6 | 0.0245515 | low |
Cytoskeletal Protein | Dynlrb1 | 0.0227117 | high |
Metabolite Interconversion Enzyme | Glrx3 | 0.0010183 | high |
Ndufa5 | 0.0473985 | low | |
Nucleic Acid Binding Protein | SNRPG | 0.0125193 | low |
Translational Protein | Rps28 | 0.0406697 | low |
COPS6 | 0.0463107 | high | |
Other Proteins | DDX5 | 0.0242271 | high |
KRT1 | 0.0326712 | low | |
NUP205 | 0.0335003 | high | |
CXorf22 | 0.0419458 | low |
2.4. Pathway Analysis of the Differentially Expressed Retinal Proteins in I/R and H2S Groups
To better understand the roles of H2S in I/R injury, we utilized the Ingenuity Pathway Analysis (IPA) software to identify the protein-protein interaction (PPI) networks and canonical pathways of the differentially expressed proteins. The most significantly affected pathways due to I/R comprised ketogenesis are, formaldehyde oxidation II, phototransduction pathway, anandamide degradation and heme degradation (Table 4). Amongst which, pathways such as ketogenesis, gamma-aminobutyric acid (GABA) receptor signaling, leucine degradation I and ketolysis, are significantly restored following H2S pre-treatment.
Table 4.
Canonical Pathways | −log(p-Value) | Changes | Molecules | |
---|---|---|---|---|
Mitochondrial Homeostasis and Function | Ketogenesis | 3.62 | Downregulated | HADHA, HMGCL |
Protein Ubiquitination Pathway | 1.7 | Upregulated | HSPA1L, PSMD13, USO1 | |
Leucine Degradation I | 1.72 | Downregulated | HMGCL | |
Ketolysis | 1.68 | Downregulated | HADHA | |
Neuronal Calcium Dysregulation | Calcium Transport I | 1.68 | Upregulated | ATP2B2 |
Cytotoxicity Regulation | Formaldehyde Oxidation II (Glutathione-dependent) | 2.37 | Downregulated | ESD |
Anandamide Degradation | 2.2 | Upregulated | FAAH | |
Purine Ribonucleosides Degradation to Ribose-1-phosphate | 1.83 | Downregulated | PNP | |
Reactive Oxygen Species (ROS) Scavenging | Heme Degradation | 2.07 | Upregulated | BLVRA |
Vitamin-C Transport | 1.31 | Downregulated | SLC2A1 | |
Neural Transduction | Phototransduction Pathway | 2.25 | Downregulated | CNGA1, GNGT1 |
GABA Receptor Signaling | 1.76 | Upregulated | AP2M1, SLC32A1 | |
Vascular Function | eNOS Signaling | 1.35 | Downregulated | CNGA1, HSPA1L |
Protein Kinase A Signaling | 1.29 | Upregulated | ACP1, CAMK2B, CNGA1 |
I/R vs. CTRL.
Compared to the CTRL group, administration of H2S also significantly modulated pathways, such as NER pathway, oxidative phosphorylation and estrogen receptor signaling (Table 5).
Table 5.
Canonical Pathways | −log(p-Value) | Changes | Molecules | |
---|---|---|---|---|
Mitochondrial Homeostasis and Function | Ketogenesis | 3.78 | Upregulated | HADHA, HMGCL |
Leucine Degradation I | 1.8 | Upregulated | HMGCL | |
Ketolysis | 1.76 | Upregulated | HADHA | |
Neural Transduction | GABA Receptor Signaling | 1.91 | Downregulated | AP2M1, SLC32A1 |
ROS Regulation | Vitamin-C Transport | 1.38 | Upregulated | SLC2A1 |
HIF1α Signaling | 0.742 | Upregulated | SLC2A1 | |
Canonical Pathways | −log(p-Value) | Changes | Molecules | |
NER pathway | 1.18 | Upregulated | COPS6 | |
Oxidative Phosphorylation | 1.16 | Downregulated | NDUFA5 | |
Estrogen Receptor Signaling | 1.04 | Upregulated | DDX5 | |
Corticotropin Releasing Hormone Signaling | 1.02 | - | KRT1 | |
Phagosome Maturation | 0.708 | - | DYNLRB1 |
(A) H2S vs. I/R. (B) H2S vs. CTRL.
To further explore the protein–protein interaction (PPI) networks of the clusters of differentially expressed proteins, functional pathway enrichment was analyzed in the I/R group, H2S-restored proteins and H2S-modulated proteins. The global view of the interactions between proteins that were differentially regulated in the I/R group is shown in Figure 4. The proteins with the most interactions were EFTUD2, AP2M1, Hadha, Heat shock 70 kDa protein 1-like (HSPA1L) and Plastin-3 (PLS3). EFTUD2 was found to obtain the highest number of PPI (13 PPIs), followed by AP2M1 with 4 PPIs.
Among the 18 proteins restored by H2S pretreatment, there is a low determined PPI. EFTUD2 and AP2M1 shown less PPIs, 8 and 3 PPIs, respectively (Figure 5A).
A number of 11 proteins were modulated by H2S compared to CTRL group, among which, COP9 signalosome complex subunit 6 (COPS6) and DDX5 have the highest number of PPIs (Figure 5B).
3. Discussion
Ever since H2S has been recognized as the third endogenous gaseous signaling molecule alongside CO and NO, its role in various physiological and pathological processes has been explored. In our previous study, endogenous H2S synthases are observed to increase in a glaucoma animal model after seven weeks of chronic elevated IOP. Furthermore, we demonstrated that administration of GYY4137, a slow-release H2S donor, significantly improved RGC survival under different glaucomatous injuries in vitro and in vivo [21]. The neuroprotective effect of H2S in the retina was partly attributed to its capability of vasorelaxation, anti-oxidative stress, neuroendocrine regulation and inflammation suppression [25] but the underlying mechanism and the specific protein interaction networks and the mechanisms involved in protective properties of H2S remain to be elucidated. Building on previous results, we employed a mass spectrometry-based proteomics approach to analyze the retinal proteome, and bio-informatics to algorithmically generate protein connections, which allowed us to identify the most plausible signaling pathway alterations related to H2S’s neuroprotective properties against ischemia-reperfusion injury in present study. This is to our knowledge, the first study to address the intricate alterations at the protein level, which can be attributed to the treatment with exogenous H2S, and to show how these molecules play a pivotal role in restoring retinal homeostasis against I/R injury in vivo.
Following I/R injury, the abundance of 48 proteins was significantly altered. Changes of the signaling pathways involved in mitochondrial homeostasis and function, calcium dysregulation, cytotoxicity regulation, reactive oxygen species (ROS) scavenging, neural transduction and vascular function were found. The proteins, which were regulated by H2S were categorized into two clusters: (1) a cluster 18 proteins, the abundance of which was significantly altered in I/R, and was then restored to normal or near normal level by H2S; (2) a cluster of 11 proteins, the abundance of which was significantly altered due to H2S administration compared to the CTRL group. Based on the results from the ingenuity pathway analysis, the signaling pathways regulated by H2S comprised iron homeostasis and ROS regulation, mitochondrial homeostasis and function, vasodilation and DNA repairing.
3.1. Changes in Iron Homeostasis and ROS Regulation
Redox mechanisms are known to partially contribute to the protective properties of H2S in various tissues. Firstly, we observed that the Slc2a1 level is significantly downregulated in I/R and restored by H2S. Slc2a1 facilitates docosahexaenoic acid (DHA), the oxidized form of vitamin C, transport across the inner blood-retina barrier and converts DHA to ascorbic acid and accumulates as ascorbic acid in the retina [26]. As the Slc2a1 level is downregulated following I/R injury, vitamin-C transport is downregulated accordingly. Vitamin C is the primary circulatory antioxidant to be quickly used and depleted when excessive ROS is generated by the pathophysiological pathways triggered by I/R injury, therefore sparing other endogenous antioxidants [27]. Oxidative stress promotes the oxidation of ascorbic acid to DHA, which is shown by studies to promote neuronal death under oxidative stress [28]. Downregulated vitamin-C transport indicates that I/R injury impaired the anti-oxidative property of the retina. H2S increased vitamin-C transport, subsequently strengthening the anti-oxidative property of the retina as opposed to the ROS generated due to I/R.
Secondly, several proteins involved in iron homeostasis, such as biliverdin reductase A (Blvra), Cyb5r3 and Glrx3, were differentially abundant due to I/R, H2S administration or both. Iron metabolism and regulation is crucial in mammals and is essential for physiological neuronal functions such as neural respiration and metabolic activities, myelin synthesis, neurotransmitter production and synaptic plasticity [29]. However, its overload triggers axonal degeneration and neuronal cell death [30]. Excessive iron may catalyze the formation of highly reactive hydroxyl radicals, which eventually induce the accumulation of ROS [31,32]. Nevertheless, it is well known that the disproportionally increased brain Fe level is correlated with neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and neurodegeneration with brain Fe accumulation.
Most of the body’s Fe is contained within the protoporphyrin ring of heme [32]. Heme is essential for the survival of organisms, while being potentially toxic. The excessive release of heme from hemoproteins can lead to the generation of unfettered oxidative stress and programmed cell death [29]. Heme degradation is therefore important for maintaining iron homeostasis and preventing its cytotoxicity and oxidative stress [33].
The abundance of Blvra, the main isoform of biliverdin reductase [34], is significantly increased due to I/R injury. Increased Blvra level corresponds to upregulated heme degradation.
Blvra is a pleiotropic enzyme primarily known for reducing heme-derived biliverdin into the powerful antioxidant and anti-nitrosative molecule bilirubin [35,36]. Bilirubin is able to inhibit free radical chain reactions and protects against oxidant-induced damage [37]. Studies reported that reducing Blvra level in cells or knockout Blvra gene in mice both led to increased oxidative stress [37,38]. On the other hand, increasing the levels of Blvra is beneficial through an increase in intracellular bilirubin generation and direct signaling through cytoprotective pathways [34,39,40].
Cyb5r3, the principal reductase in mitochondria, is also significantly upregulated due to I/R injury, and can be restored by H2S. Cyb5r3 is also a heme reductase and recycles oxidized heme (Fe3+) back to its reduced form (Fe2+) [41]. Upregulation of Blvra and Cyb5r3 levels following I/R injury is likely to confer self-protection against oxidative stress.
Glrx3 level was the most significantly modulated by H2S when compared to the control group, while it was not impacted by I/R injury. Depletion of Glrx3 in mammalian cells was associated with moderate deficiencies of cytosolic Fe-S cluster enzymes and evidence of altered iron homeostasis [42]. Overexpressed Glrx3 can compensate for the lack of other reducing equivalents [43].
Glrx3 belongs to the glutaredoxin family, it utilizes the reducing power of glutathione to maintain and regulate the cellular redox state and is essential for iron-sulfur (Fe-S) cluster assembly [44,45]. Iron-sulfur clusters are ancient, ubiquitous cofactors composed of iron and inorganic sulfur which participate in numerous biological processes [46,47,48,49].
In mammalian cells, Glrx3 localizes to the cytosol and it has been proposed that it plays dual roles in iron trafficking and regulation [50,51]. Glrx3 is a monothiol glutaredoxin, being able to form (2Fe-2S) cluster-bridged dimers and deliver Fe-S clusters to recipient proteins [52,53].
Detoxification of neural Fe overload is a potential therapeutic approach in the treatment of neurodegenerative disease. Based on the results of proteomic and IPA analysis, we assume that, when exposed to oxidative stress, cells increase their capability to reduce oxidized heme and to degrade it, which partially contributes to a self-protective mechanism that reduces the deleterious effects of free heme. H2S plays a similar reducing role as Cyb5r3 in recycling oxidized heme to its reduced state; the abundance of Cyb5r3 was thus not increased when H2S was present. Nevertheless, H2S has shown a strong association with Glrx3, which is able to regulate cellular iron homeostasis [54,55].
3.2. Changes in Retinal Metabolism, Mitochondrial Homeostasis and Function
As mentioned above, the abundance of Slc2a1 is significantly downregulated in I/R and restored by H2S to near normal levels, which also corresponds to increased HIF1α signaling. Slc2a1 abundance in HIF1α signaling plays a key role in promoting neuronal survival by mediating the endogenous protective responses after hypoxia-ischemia. In glaucoma mice, decreased HIF1α expression is observed to be correlated with RGC loss [56]. H2S regulates HIF1 factors in different patterns, depending on different cell types and experimental conditions. It increases expression of the HIF1α in rat brain capillary endothelial cells and in mouse spinal-cord primary culture [57,58], and inhibits HIF1 activation in human hepatoma Hep3B cells, cervical carcinoma HeLa cells and aortic smooth-muscle cells [59,60].
Our proteomic data indicate that H2S administration increased HIF1α signaling. Upregulating expression of HIF1α induces an increase of aerobic glycolysis, which transforms glucose to lactate and generates nicotinamide adenine dinucleotide (NAD+) [61]. HIF1 also directly induces pyruvate dehydrogenase kinase 1 [62], which phosphorylates the pyruvate dehydrogenase (PDH) complex, and consequently inhibits PDH complex from catalyzing pyruvate to form acetyl CoA. This fuels the mitochondrial tricarboxylic acid cycle (TCA) cycle, which provides the mitochondrial NADH needed to power electron transport. Hence, HIF1α actively represses mitochondrial respiration.
Furthermore, in this study, H2S reduced the abundance of NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 5 (Ndufa5), which subsequently also decreased mitochondrial respiration. Ndufa5, localizes to the inner mitochondrial membrane and is an accessory sub-unit of complex I [63]. Reducing Ndufa5 suppresses complex I activity [64,65]. It is generally believed, that mitochondrial complex I deficiency contributes to the process of neurodegeneration because of reduced adenosine triphosphate (ATP) production, oxygen consumption and increased ROS production. However, complex I has been reported as a site of mitochondrial ROS generation [66,67], and actively suppressing its activity may actually be protective. Neuronal complex I deficiency is not correlated with the neurodegeneration, mitochondrial DNA damage in Parkinson’s disease brain, nor in mice with a central nervous system knockout of Ndufa5 [64,68]. It has been shown in neurodegenerative disorders that reversible inhibition of complex I can be protective against ischemia-reperfusion injury by modifying mitochondrial ROS production [69,70].
Studies strongly suggest that active suppression of the TCA cycle, mitochondrial respiration and ROS production, as well as augmentation of ATP levels, are crucial for the cell survival under I/R injury [62,71]. We assume that by suppressing mitochondrial respiration through upregulating HIF1-α and downregulating Ndufa5 levels, H2S reduces mitochondrial oxidative phosphorylation, thereby repressing mitochondrial oxygen consumption and resulting in the relative increase of intracellular oxygen tension and limited ROS production under I/R.
As discussed above, mitochondrial PDH activity is attenuated by HIF1α following H2S administration. Neurons usually prefer glucose for energy, but when mitochondrial metabolism of pyruvate is limited, ketone bodies can be oxidized and release the only alternative source of acetyl CoA for neurons [72]. Using ketone bodies as an alternative energy source has shown neuroprotective effects in Alzheimer’s disease, Parkinson’s disease and ischemic and traumatic brain injury [73,74,75,76,77,78]. The metabolic pathway that produces ketone bodies is ketogenesis. In this study, the signaling pathways most significantly downregulated by I/R injury and then restored by H2S were ketogenesis, ketolysis and leucine degradation.
In comparison to glucose, ketone bodies have a higher inherent energy [79]. As ketone bodies provide more energy per unit of oxygen than glucose [80,81], in states of metabolic stress such as I/R injury, ketone bodies are more energy-efficient fuel for neurons. They can also bypass the inhibited PDH complex and maintain the metabolites of TCA cycle, therefore permitted continued ATP production under ischemia.
Administration of H2S has shown evidence of actively suppressing oxidative phosphorylation and limiting the utilization of glucose as the energy source, therefore increasing intracellular oxygen tension under ischemia and limiting ROS production during reperfusion. Furthermore, H2S promotes the utilization of ketone bodies as an alternative energy source, which is more energy-efficient than glucose and maintains ATP production. H2S therefore enhanced the ability of retinal neurons to withstand metabolic stress induced by I/R, which would normally deplete the resilience of the neurons and result in neuronal cell loss (see in Figure 6).
3.3. Changes in Retinal Vascular Function
Decreased average blood flow in the retina, optic nerve head and choroidal circulations is also demonstrated in glaucoma patients [82,83,84]. The “vascular theory” of glaucoma hypothesizes RGC loss as a consequence of insufficient blood supply [85]. Vasospasm and autoregulatory dysfunction have been postulated to reduce ocular blood flow [86]. Increased IOP has also been shown to reduce vascular caliber in rat retina while H2S acted as a vasodilator in our previous studies [21]. H2S can be endogenously generated in vascular smooth muscle cells. Its vasorelaxant potency is partially mediated by a functional endothelium [87].
However, I/R is known to cause endothelial dysfunction. In this study, eNOS signaling is downregulated following I/R injury. Endothelium-derived NO is a critical regulator of vascular homeostasis and tone [88]. NO continually regulates the diameter of blood vessels and maintains an anti-apoptotic environment in the vessel wall [89].
Downregulation of eNOS signaling is an indicator of impaired endothelial function, which results in diminished microcirculation and reduced response to endothelial-dependent vasodilators and vasoconstrictors. This causes dysregulated blood flow and loss of the endothelial barrier.
While eNOS signaling is downregulated, protein kinase A (PKA) signaling is significantly upregulated following I/R. PKA represents a signaling hub for a large variety of hormones, neurotransmitters and cytokines [90]. PKA has been shown to regulate different aspects of endothelial cell physiology [91,92,93], and to inhibit angiogenesis when activated [94,95]. Upregulation of PKA is likely a self-protective mechanism.
Furthermore, one of the most significantly upregulated proteins I/R, which can be restored by H2S to normal levels, is Cyb5r3. It is the principal reductase involved in the mitochondrial amidoxime reducing component (mARC)-containing enzyme system [96]. In vascular smooth muscle, Cyb5r3 functions as a soluble guanylyl cyclase (sGC) heme iron reductase, and is critical for vasodilation [97]. Through its reductase activity, Cyb5r3 maintains NO-sGC-cGMP function [98]. The NO-sGC-cGMP pathway in aortic smooth muscle cell (SMC) is known to relax SMC and dilate vessels [98].
Hydrogen sulfide and the −SH anion reduce a variety of organic substrates [99]. It is reasonable to assume that H2S plays a similar reducing role as Cyb5r3 in maintaining vascular relaxation and enabling a less constricted vascular environment due to I/R.
Although the abundance of DDX5 was not influenced by I/R injury, it is significantly more abundant following the administration of H2S. As DDX5 regulates the expression of a number of key regulators upstream of the estrogen-receptor [100], estrogen-receptor signaling was also significantly upregulated in our PPI results.
Increasing evidence suggests that estrogen exposure may have a neuroprotective effect on the progression of glaucoma and may alter its pathogenesis [101]. The vasodilation caused by estrogen and its effects on aqueous humor outflow may contribute [102]. These estrogen receptors are abundantly expressed throughout the eye, and in particular the retina and more specifically in the RGC [103,104]. In various CNS injuries and diseases, the activation of estrogen receptor signaling has shown neuroprotective effects via attenuation of neuro-inflammation and neurodegeneration [105]. In different animal models of RGC degeneration, activation of estrogen receptor attenuated RGC apoptosis under acute elevated IOP [106]; impaired estrogen receptor expression is observed in a mouse model with early RGC apoptosis [107]; and in Leber’s hereditary optic neuropathy cells activating estrogen receptors improve cell viability by reducing apoptosis [108]. Moreover, inhibition of estrogen synthesis is associated with IOP elevation and reduced RGC counts in female mice [109] and blockage of estrogen receptor signaling in rats intensifies impairment in visual function and retinal structure after ocular hypertension [110]. Although estrogen receptor signaling was not impacted by I/R injury in our study, activating estrogen receptor signaling via upregulating DDX5 is still one of the possible pathways through which H2S exerts protective effects and partially contributes to its capability of vasorelaxation, anti-oxidative stress and inflammation suppression.
H2S also significantly downregulated annexin A6 compared to the control group, which is a calcium dependent phospholipid binding protein [111].
Annexins are important in Ca(2+)-induced neurotoxicity or neuroprotection [112]. Annexin A6 has been shown to play a central role in vascular remodeling processes [113]. It has been demonstrated that annexin A6 accumulates and converts exosomes in vascular smooth muscle cells into calcifications under calcium stress, which is known to be induced by I/R [113]. Vascular smooth muscle cells contribute significantly to physiological regulation of vascular tone and arterial blood pressure [114]. The presence of coronary artery calcification is significantly associated with raised IOP regardless of conventional cardiovascular risk factors [115]. By reducing the abundance of annexin A6, H2S potentially makes the calcification in vascular smooth muscle cells subside due to I/R, thus maintaining vascular autoregulation.
PKA signaling and Cyb5r3 level is upregulated, likely serving as a self-protective mechanism to maintain endothelial function and vasodilation against I/R injury, while eNOS signaling is downregulated as an indication of endothelial dysfunction. Administration of H2S regulated the abundance of Cyb5r3 and activated estrogen receptor signaling to facilitate vascular relaxation. H2S also reduced the abundance of annexin A6, which plays a central role in artery calcification. Combined together, H2S enabled a less constricted vascular environment in the retina, thereby resulting in better retinal perfusion to counteract I/R injury (see Figure 7).
3.4. Changes in GABA Receptor Signaling
GABA receptor signaling is the most impacted signaling pathway by I/R and this can be restored by H2S. The AP2M1 and SLC32A1 levels are upregulated due to I/R, which correspond to upregulated GABA receptor signaling. gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian brain [116]. In the retina, GABA is similarly important in neural inhibition with approximately 40% of all retinal cells having been described as GABAergic [117]. GABA-containing vesicles release the neurotransmitter into the synaptic cleft to bind with GABA receptors present on the post-synaptic neuron [118].
SLC32A1, solute carrier family 32 (GABA vesicular transporter) member 1, is a transmembrane transporter which is responsible for the storage of GABA or glycine in synaptic vesicles [119]. AP2M1 is highly expressed in the central nervous system [120,121], and encodes the μ-subunit of the adaptor protein complex 2 (AP-2) [122]. AP-2 regulates the neuronal surface levels of GABA and glutamate receptors [123,124]. An imbalance between excitatory and inhibitory synaptic transmission is thought to contribute to excitotoxicity and neuronal cell death during ischemic insult. AP-2 was found to be crucial in reducing the loss of synaptic GABA receptors during simulated ischemia in the rat brain [125]. Increased abundance of SLC32A1 and AP2M1 suggests raised retinal GABA levels following I/R injury, which may occur in order to maintain excitatory/inhibitory balance, thereby improving the survival of RGCs, the latter being most susceptible to extracellular glutamate.
However, similar to glutamate, the functions of GABA are also controversial. There is evidence that the retina is extremely sensitive to abnormally accumulated GABA and its resulting toxicity, particularly in the presence of ischemia [126,127,128]. An antiepileptic drug, vigabatrin (gamma-vinyl GABA), exerts its effect by increasing GABA levels [129]; as the drug increases retinal GABA levels much more significantly than in the brain and retina has a lower tolerance to GABA toxicity than the brain [127,128], one third of patients receiving vigabatrin present binasal visual field loss [130].
GABA also has a role in the regulation of vascular tone [127]. GABA receptors are known to interact with perivascular astrocytes which synthesize vasoactive materials [131,132]. In the rat retina, GABA is shown to be capable of eliciting both vasodilator and vasoconstrictor responses but endogenous GABA is unlikely to be an important regulator of resting vascular diameter and blood flow in the retina [133].
The exact role of GABA receptor signaling in this study is unclear but the results certainly raise intriguing questions about the involvement of GABA receptor signaling in neurodegeneration and the interaction between GABA signaling and H2S.
3.5. Changes in DNA Repair
The nucleotide excision repair (NER) pathway is at the top of the canonical pathways modulated by H2S, with a particularly significant upregulation of COPS6 level. In combination with the ubiquitin (Ub) proteasome system (UPS) the COP9 signalosome controls the stability of cellular regulators [134] and regulates several important intracellular pathways, including DNA repair, cell cycle, developmental changes, and some aspects of immune responses [135,136,137].
COPS6 has been shown to be cleaved by caspase 3 during apoptosis in vitro and in vivo [138] and this cleavage can be completely blocked by specific caspase 8 inhibitor [139]. Upregulation of COPS6 led to upregulation of the NER pathway, one of the major cellular DNA repair pathways for the removal of bulky helix lesions [140,141]. Enhancement of the NER pathway has shown protective effects in peripheral neurons both in vitro and in vivo [142]. The roles of DNA repair in neuronal cell survival and the response to aging and ROS such as that generated by mitochondrial respiration in glaucoma is of particular interest. The promotion of DNA repair by activation of the NER pathway through COP9 signalosome subunit upregulation could be an interesting aspect to explore in future studies.
Neurodegenerative diseases are characterized by decades of apparent normality, during which local deficits are compensated. Eventually the deficits become too accentuated or the compensatory mechanisms fail [143]. From the results we obtained in this study, I/R injury led to changes in ROS regulation, retinal metabolism, mitochondrial homeostasis and function, retinal vascular function and metal homeostasis, with over half of the altered pathways in the I/R group being self-protective mechanisms. H2S provided additional support where self-protective mechanisms fell short and demonstrated DNA repair properties, eventually providing neurons a better outcome against I/R injury.
Admittedly there are limitations in this study. Firstly, individual retinal samples were deliberately pooled into biological replicates to minimize inter-individual variations [144,145]. The exact role H2S plays in neurodegeneration within the retina is largely vague and still awaits to be thoroughly elucidated. Due to the limitation of sample material and the variety of the signaling pathways H2S is involved in, we cannot confirm the differentially expressed proteins by a second technique in the present study design. As the foremost study providing a thorough overview of the retina proteome changes related to neuroprotective properties of H2S in the retina, the main focus was to acquire a comprehensive perspective of the complex interaction between different proteins. Building on these results, different techniques will definitely be used to confirm the differentially expressed proteins and altered signaling pathways in our future studies.
Secondly, the results attained from the ischemia/reperfusion model are not necessarily valid in other glaucomatous models. There are various experimental models of glaucoma in the marketplace; each of them has specific pros and cons. It seems that degeneration caused by chronic elevated IOP mimics the characteristics of glaucoma better than I/R model. Clinical observations have demonstrated retinal vascular abnormalities and impaired blood flow at the optic nerve head which suggest ischemia plays a key role in the pathogenesis of glaucoma [146,147]. A pure ischemic lesion certainly cannot represent the glaucomatous damage; reperfusion injury is also present in glaucoma patients [148]. It is evident that IOP fluctuations are more damaging than a stabled increased IOP, and reduced circulation due to vascular dysregulation is more damaging than reduced circulation due to arteriosclerosis [149].
This study provides, for the first time, an overall insight into the mainstay retinal proteins and pivotal signaling pathways that interact with H2S to maintain retinal homeostasis against I/R injury. In particular, it reveals that exogenous H2S activates the pathways linked to iron regulation, ROS scavenging, the modulation of mitochondrial homeostasis and function, maintenance of retinal vascular function and GABA receptor signaling. H2S may be a promising and effective therapeutic tool for glaucoma. The findings presented here point to directions for further research, for example, exploring the significance of these identified proteins and pathways and investigating related data from other glaucoma models.
4. Materials and Methods
The overview of sampling and proteomics workflow used in this study is presented in Figure 8.
4.1. Animals
Female Sprague–Dawley rats (n = 12; 250–300 g) at the same age were used for glaucoma animal model in this study. The use of animals for research purposes was approved by the Health Investigation Office Rhineland-Palatinate (permission number: 14-1-085; approvals date: 13 October 2014). All experimental procedures were in accordance with the Association of Research in Vision and Ophthalmology (ARVO)—Statement for the Use of Animals in Ophthalmic and Vision Research, and the guidelines of the Institutional Animal Care and Use Committee. Animals were kept under a day- and night-cycle of 12 h at the Translational Animal Research Center (TARC) of the University Medical Center of Johannes-Gutenberg University Mainz.
Minimizing the discomfort and pain for the animals was prioritized in the experimental interventions. A mixture of medetomidine hydrochlorid (Dorbene vet., Pfizer, New York, NY, USA) and ketamine (Inresa Arzneimittel, Freiburg, Germany) was administered intraperitoneally for anesthesia, and oxybuprocain (Novesine, OmniVision, Puchheim, Germany) was applied topically to ocular surfaces. To reduce post operation pain, novaminsulfon (Novalgin, Ratiopharm, Ulm, Germany) was injected subcutaneously after intervention. Health condition and general behavior of the animals were observed daily by TARC staff.
4.2. Intravitreal Injection of GYY4137
Animals were anesthetized as described above, following topical anesthesia, 3 μL of GYY4137, a H2S slow-releasing donor (SIGMA-ALDRICH; Darmstadt, Germany) was injected into the vitreous body with Hamilton syringe (SIGMA-ALDRICH; Darmstadt, Germany) paired with 33-gauge needle. The injection volume was 3 μL to achieve optimal distribution of the compound and minimum disruption to the IOP [150]. The injection needle was retained intravitreally for 15 s to avoid reflux. The intraocular concentration of GYY4137 was approximately 100 nM as average vitreous volume of an adult rat eye is approximately 56 uL [150].
4.3. Ischemia-Reperfusion Injury Model
The retinal ischemia-reperfusion (I/R) injury model is a well-established animal model which imitates the clinical manifestations of retinal vascular occlusion diseases and acute glaucoma. It has also been widely adapted to study retinal neuronal cell damage. Female Sprague-Dawley rats (n = 12; 250–300 g) were anesthetized, with six receiving an intravitreal injection of GYY4137 in the left eye and the other six receiving intravitreal injections of saline, as described as above. The saline injection group served as the corresponding control with retinae from untouched contralateral eyes being assigned as baseline controls. Following the intravitreal injection, the anterior chamber was entered from the superotemporal cornea with a 30-gauge needle (see Figure 8A). The needle was connected to a sterile saline container, which was lifted until IOP was elevated to 55 mmHg for a period of 60 min. IOP was measured by a rebound-Tonolab (iCare, Vantaa, Finland) for rodent. Central cornea, lens and other surrounding tissues were carefully avoided and not injured in the process. The iris turned pale and the retina lost its red reflex during the procedure, thus confirming the ischemic condition of the eye. Animals were kept alive for 24 h after the intervention for sufficient reperfusion injury.
4.4. Preparation of Retinal Explants
Sprague-Dawley rats were sacrificed under CO2 atmosphere. Eyes were explanted immediately post-mortem and retinae were harvested and flat-mounted as previously described [21]. In short, the eye is dissected into the anterior segment and the optic cup. Intact retina was harvested from the optic cup and flat-mounted on the Millipore filters (Millipore; Millicell, Cork, Ireland) with the ganglion cell side up, vitreous body was then carefully removed (Figure 8B).
4.5. Quantification of Retinal Ganglion Cells
One quarter of each retinal explant was carefully separated under microscope for subsequent immunohistochemical staining against the brain-specific homeobox/POU domain protein 3A (Brn3a). Unlike Thy1, which is another RGC-specific antigen, the expression pattern of Brn3a does not change after retinal injury and the levels of Brn3a protein are decreased with time after retinal injury, which is in agreement with the loss of RGC [151]. Therefore, Brn3a immunodetection is a powerful tool to assess RGC survival in rat injury models [152,153]. Retinal tissue (n = 6 quarters/group) was fixed and stained as previously described [154]. Immunofluorescent RGCs were visualized and photographed with a fluorescent microscope (Carl Zeiss, Ltd., Hertfordshire, UK). Images of retinal whole mounts were photographed from 4 different regions of each quadrant of the retina (Figure 1) using a Zeiss fluorescent microscope (Carl Zeiss, Ltd., Hertfordshire, UK). Images were captured at a 20-fold magnification using a fluorescent camera (Carl Zeiss, Ltd., Hertfordshire, UK). Total numbers of Brn3a-positive cells were counted with the assistance of ImageJ (ImageJ Fiji v_1, total = 4 counts/quadrant, and six retinal quadrants per treatment group). The mean number of RGCs per quadrant was calculated from a mean count at each of the 4 different regions.
4.6. Mass Spectrometry Sample Preparation
The remaining retinal explants were rinsed in ice-cold PBS to remove contaminants and weighed immediately thereafter. Retinal protein extraction from each piece of retina was carried out using T-PER tissue protein extraction reagent (Thermo Scientific Inc., Waltham, MA, USA) following an in-house established method, as described by Manicam et al. [155]. Protein concentration of each eluate was measured by standard bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA) as per manufacturer’s instructions. Following protein measurements, retinal protein samples from respective groups were pooled equally into three biological replicates, represented by R1, R2 and R3. From each replicate, 50 μg protein was subjected to polyacrylamide gel electrophoresis (PAGE). Protein lanes were sliced into 25 bands per replicate and destained, reduced, alkylated, dehydrated and subjected to in-gel trypsin digestion at 37 °C overnight. The peptides were then extracted firstly with acetonitrile and then with a mixture of 5% formic acid and acetonitrile 1:2 (v/v), the supernatant was pooled. The extracted peptides were further purified by SOLAμ SPE plates and cartridges (Thermo Scientific Inc., Waltham, MA, USA) following manufacture’s instructions. The eluate was dried in SpeedVac and dissolved in 10 μL of 0.1% trifluoroacetic acid (TFA) for LC-MS/MS analysis.
The continuum MS data was collected by an ESI-LTQ Orbitrap XL-MS system (Thermo Scientific, Bremen, Germany). The tandem MS spectra were searched against UniProt database (Homo sapiens; Rattus; 21.11.2018). A target-decoy-based false discovery rate (FDR) was set to 0.01 for identification of peptide and protein.
(Figure 8C–F. The detailed sample preparation procedure and general parameters of the instrument can be found in Supplementary Data S3 “Mass Spectrometry Sample Preparation” and Supplementary Data S4 “MaxQuant parameters”)
4.7. Bioinformatics, Functional Annotation and Pathways Analyses and Statistics
Data generated from MaxQuant analysis was subjected to further statistical analysis, carried out with Perseus [156]. Briefly, the data were filtered with a minimum of three valid values in at least one group. The missing values were replaced from normal distribution (width, 0.3; down shift, 1.8) in Perseus. All label-free quantification (LFQ) intensities were subject to a log2 transformation. Followed by a Student’s two-sample t-test for the group’s comparison with p < 0.05 to identify the significantly differentially expressed proteins. Unsupervised hierarchical clustering analysis was done with the z-scores of the LFQ intensities following Euclidean distance (linkage = average; preprocess with k-means) and a heat map is generated to demonstrate the result.
Furthermore, the gene names of significantly differentially expressed proteins (p < 0.05) in each group were subject to functional annotation and pathways analyses by Ingenuity Pathway Analysis (v01-04, IPA; Ingenuity QIAGEN, Redwood City, CA, USA) (https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). Using Benjamini–Hochberg multiple testing correction (−log B–H > 1.3), top canonical pathways of the differentially expressed proteins were presented with p-values calculated (Figure 8G,H).
Prism 8 software (GraphPad Software, Inc., San Diego, CA, USA) was used in this study for statistical calculations of RGC quantification and displaying of the figures. The averaged RGC density was calculated per mm2. Data values are expressed as the mean ± SD. Significance of difference between groups was determined by 1-way ANOVA. Results were considered to be statistically significant when p < 0.05 (Figure 8I).
Supplementary Materials
The following are available online at https://www.mdpi.com/1424-8247/13/9/213/s1, Supplementary Data S1: Total proteins, Supplementary Data S2: Differentially expressed proteins, Supplementary Data S3: Mass Spectrometry Sample Preparation, Supplementary Data S4: Maxquant parameters.
Author Contributions
Conceptualization, H.L. and V.P.; methodology, H.L., N.P. and V.P.; software, H.L., N.P. and C.M.; validation, H.L. and V.P.; formal analysis, H.L., N.P. and C.M.; investigation, H.L.; resources, V.P.; data curation, H.L. and V.P.; writing—original draft preparation, H.L.; writing—review and editing, C.M., K.M. and V.P.; visualization, H.L.; supervision, V.P.; project administration, V.P.; funding acquisition, V.P. All authors have read and agreed to the published version of the manuscript.
Funding
This research was supported by Deutsche Forschungsgemeinschaft (DFG; Grant PR1569-1-1).
Conflicts of Interest
The authors declare no conflict of interest.
References
- 1.Flaxman S.R., Bourne R.R.A., Resnikoff S., Ackland P., Braithwaite T., Cicinelli M.V., Das A., Jonas J.B., Keeffe J., Kempen J.H., et al. Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. Lancet Glob. Health. 2017;5:e1221–e1234. doi: 10.1016/S2214-109X(17)30393-5. [DOI] [PubMed] [Google Scholar]
- 2.Almasieh M., Wilson A.M., Morquette B., Cueva Vargas J.L., Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 2012;31:152–181. doi: 10.1016/j.preteyeres.2011.11.002. [DOI] [PubMed] [Google Scholar]
- 3.Keating D.J. Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J. Neurochem. 2008;104:298–305. doi: 10.1111/j.1471-4159.2007.04997.x. [DOI] [PubMed] [Google Scholar]
- 4.Tabassum R., Jeong N.Y., Jung J. Therapeutic importance of hydrogen sulfide in age-associated neurodegenerative diseases. Neural Regen. Res. 2020;15:653–662. doi: 10.4103/1673-5374.266911. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Snyder S.H., Jaffrey S.R., Zakhary R. Nitric oxide and carbon monoxide: Parallel roles as neural messengers. Brain Res. Brain Res. Rev. 1998;26:167–175. doi: 10.1016/S0165-0173(97)00032-5. [DOI] [PubMed] [Google Scholar]
- 6.Verma A., Hirsch D.J., Glatt C.E., Ronnett G.V., Snyder S.H. Carbon monoxide: A putative neural messenger. Science. 1993;259:381–384. doi: 10.1126/science.7678352. [DOI] [PubMed] [Google Scholar]
- 7.Bucolo C., Drago F. Carbon monoxide and the eye: Implications for glaucoma therapy. Pharmacol. Ther. 2011;130:191–201. doi: 10.1016/j.pharmthera.2011.01.013. [DOI] [PubMed] [Google Scholar]
- 8.Liu R., Flammer J., Haefliger I.O. Isoproterenol, forskolin, and cAMP-induced nitric oxide production in pig ciliary processes. Investig. Ophthalmol. Vis. Sci. 1999;40:1833–1837. [PubMed] [Google Scholar]
- 9.Meyer P., Champion C., Schlotzer-Schrehardt U., Flammer J., Haefliger I.O. Localization of nitric oxide synthase isoforms in porcine ocular tissues. Curr. Eye Res. 1999;18:375–380. doi: 10.1076/ceyr.18.5.375.5355. [DOI] [PubMed] [Google Scholar]
- 10.Fleischhauer J.C., Beny J.L., Flammer J., Haefliger I.O. NO/cGMP pathway activation and membrane potential depolarization in pig ciliary epithelium. Investig. Ophthalmol. Vis. Sci. 2000;41:1759–1763. [PubMed] [Google Scholar]
- 11.Giuffrida S., Bucolo C., Drago F. Topical application of a nitric oxide synthase inhibitor reduces intraocular pressure in rabbits with experimental glaucoma. J. Ocul. Pharmacol. Ther. 2003;19:527–534. doi: 10.1089/108076803322660440. [DOI] [PubMed] [Google Scholar]
- 12.Neufeld A.H., Das S., Vora S., Gachie E., Kawai S., Manning P.T., Connor J.R. A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J. Glaucoma. 2002;11:221–225. doi: 10.1097/00061198-200206000-00010. [DOI] [PubMed] [Google Scholar]
- 13.Neufeld A.H., Sawada A., Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA. 1999;96:9944–9948. doi: 10.1073/pnas.96.17.9944. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Maher P., Hanneken A. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. Investig. Ophthalmol. Vis. Sci. 2005;46:4796–4803. doi: 10.1167/iovs.05-0397. [DOI] [PubMed] [Google Scholar]
- 15.Patil K., Bellner L., Cullaro G., Gotlinger K.H., Dunn M.W., Schwartzman M.L. Heme oxygenase-1 induction attenuates corneal inflammation and accelerates wound healing after epithelial injury. Investig. Ophthalmol. Vis. Sci. 2008;49:3379–3386. doi: 10.1167/iovs.07-1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Stagni E., Privitera M.G., Bucolo C., Leggio G.M., Motterlini R., Drago F. A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits. Br. J. Ophthalmol. 2009;93:254–257. doi: 10.1136/bjo.2007.137034. [DOI] [PubMed] [Google Scholar]
- 17.Gadalla M.M., Snyder S.H. Hydrogen sulfide as a gasotransmitter. J. Neurochem. 2010;113:14–26. doi: 10.1111/j.1471-4159.2010.06580.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Kimura H. Signaling molecules: Hydrogen sulfide and polysulfide. Antioxid. Redox Signal. 2015;22:362–376. doi: 10.1089/ars.2014.5869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Biermann J., Lagreze W.A., Schallner N., Schwer C.I., Goebel U. Inhalative preconditioning with hydrogen sulfide attenuated apoptosis after retinal ischemia/reperfusion injury. Mol. Vis. 2011;17:1275–1286. [PMC free article] [PubMed] [Google Scholar]
- 20.Si Y.F., Wang J., Guan J., Zhou L., Sheng Y., Zhao J. Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. Br. J. Pharmacol. 2013;169:619–631. doi: 10.1111/bph.12163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Liu H., Anders F., Thanos S., Mann C., Liu A., Grus F.H., Pfeiffer N., Prokosch-Willing V. Hydrogen sulfide protects retinal ganglion cells against glaucomatous injury in vitro and in vivo. Investig. Ophthalmol. Vis. Sci. 2017;58:5129–5141. doi: 10.1167/iovs.17-22200. [DOI] [PubMed] [Google Scholar]
- 22.Yang G., Wu L., Jiang B., Yang W., Qi J., Cao K., Meng Q., Mustafa A.K., Mu W., Zhang S., et al. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587–590. doi: 10.1126/science.1162667. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kaneko Y., Kimura Y., Kimura H., Niki I. L-Cysteine inhibits insulin release from the pancreatic beta-cell: Possible involvement of metabolic production of hydrogen sulfide, a novel gasotransmitter. Diabetes. 2006;55:1391–1397. doi: 10.2337/db05-1082. [DOI] [PubMed] [Google Scholar]
- 24.Zhang H., Bhatia M. Hydrogen sulfide: A novel mediator of leukocyte activation. Immunopharmacol. Immunotoxicol. 2008;30:631–645. doi: 10.1080/08923970802278045. [DOI] [PubMed] [Google Scholar]
- 25.Liu H., Mercieca K., Anders F., Prokosch V. Hydrogen sulfide and beta-synuclein are involved and interlinked in the aging glaucomatous retina. J. Ophthalmol. 2020;2020:8642135. doi: 10.1155/2020/8642135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Hosoya K., Nakamura G., Akanuma S., Tomi M., Tachikawa M. Dehydroascorbic acid uptake and intracellular ascorbic acid accumulation in cultured Muller glial cells (TR-MUL) Neurochem. Int. 2008;52:1351–1357. doi: 10.1016/j.neuint.2008.02.001. [DOI] [PubMed] [Google Scholar]
- 27.Spoelstra-de Man A.M.E., Elbers P.W.G., Oudemans-Van Straaten H.M. Vitamin C: Should we supplement? Curr. Opin. Crit. Care. 2018;24:248–255. doi: 10.1097/MCC.0000000000000510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Garcia-Krauss A., Ferrada L., Astuya A., Salazar K., Cisternas P., Martinez F., Ramirez E., Nualart F. Dehydroascorbic acid promotes cell death in neurons under oxidative stress: A protective role for astrocytes. Mol. Neurobiol. 2016;53:5847–5863. doi: 10.1007/s12035-015-9497-3. [DOI] [PubMed] [Google Scholar]
- 29.Gozzelino R. The pathophysiology of heme in the brain. Curr. Alzheimer Res. 2016;13:174–184. doi: 10.2174/1567205012666150921103304. [DOI] [PubMed] [Google Scholar]
- 30.Zhang D.L., Ghosh M.C., Rouault T.A. The physiological functions of iron regulatory proteins in iron homeostasis—An update. Front. Pharmacol. 2014;5:124. doi: 10.3389/fphar.2014.00124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Gutteridge J.M., Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. N. Y. Acad. Sci. 2000;899:136–147. doi: 10.1111/j.1749-6632.2000.tb06182.x. [DOI] [PubMed] [Google Scholar]
- 32.Gozzelino R., Arosio P. Iron homeostasis in health and disease. Int. J. Mol. Sci. 2016;17:130. doi: 10.3390/ijms17010130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Alavi F.S., Gheidi M., Zahedi M., Safari N., Ryde U. A novel mechanism of heme degradation to biliverdin studied by QM/MM and QM calculations. Dalton Trans. 2018;47:8283–8291. doi: 10.1039/C8DT00064F. [DOI] [PubMed] [Google Scholar]
- 34.Kapitulnik J., Maines M.D. Pleiotropic functions of biliverdin reductase: Cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci. 2009;30:129–137. doi: 10.1016/j.tips.2008.12.003. [DOI] [PubMed] [Google Scholar]
- 35.Stocker R. Antioxidant activities of bile pigments. Antioxid. Redox Signal. 2004;6:841–849. doi: 10.1089/ars.2004.6.841. [DOI] [PubMed] [Google Scholar]
- 36.Barone E., Trombino S., Cassano R., Sgambato A., De Paola B., Di Stasio E., Picci N., Preziosi P., Mancuso C. Characterization of the S-denitrosylating activity of bilirubin. J. Cell. Mol. Med. 2009;13:2365–2375. doi: 10.1111/j.1582-4934.2008.00680.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Chen W., Maghzal G.J., Ayer A., Suarna C., Dunn L.L., Stocker R. Absence of the biliverdin reductase-a gene is associated with increased endogenous oxidative stress. Free Radic. Biol. Med. 2018;115:156–165. doi: 10.1016/j.freeradbiomed.2017.11.020. [DOI] [PubMed] [Google Scholar]
- 38.Sharma N., Tramutola A., Lanzillotta C., Arena A., Blarzino C., Cassano T., Butterfield D.A., Di Domenico F., Perluigi M., Barone E. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer’s disease. Neurobiol. Dis. 2019;125:176–189. doi: 10.1016/j.nbd.2019.02.003. [DOI] [PubMed] [Google Scholar]
- 39.O’Brien L., Hosick P.A., John K., Stec D.E., Hinds T.D., Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol. Metab. TEM. 2015;26:212–220. doi: 10.1016/j.tem.2015.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Tudor C., Lerner-Marmarosh N., Engelborghs Y., Gibbs P.E., Maines M.D. Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem. J. 2008;413:405–416. doi: 10.1042/BJ20080018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Durgin B.G., Hahn S.A., Schmidt H.M., Miller M.P., Hafeez N., Mathar I., Freitag D., Sandner P., Straub A.C. Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation. JCI Insight. 2019;4 doi: 10.1172/jci.insight.129183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Haunhorst P., Hanschmann E.M., Brautigam L., Stehling O., Hoffmann B., Muhlenhoff U., Lill R., Berndt C., Lillig C.H. Crucial function of vertebrate glutaredoxin 3 (PICOT) in iron homeostasis and hemoglobin maturation. Mol. Biol. Cell. 2013;24:1895–1903. doi: 10.1091/mbc.e12-09-0648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Aslund F., Ehn B., Miranda-Vizuete A., Pueyo C., Holmgren A. Two additional glutaredoxins exist in Escherichia coli: Glutaredoxin 3 is a hydrogen donor for ribonucleotide reductase in a thioredoxin/glutaredoxin 1 double mutant. Proc. Natl. Acad. Sci. USA. 1994;91:9813–9817. doi: 10.1073/pnas.91.21.9813. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Lillig C.H., Berndt C., Holmgren A. Glutaredoxin systems. Biochim. Biophys. Acta. 2008;1780:1304–1317. doi: 10.1016/j.bbagen.2008.06.003. [DOI] [PubMed] [Google Scholar]
- 45.Qi W., Li J., Chain C.Y., Pasquevich G.A., Pasquevich A.F., Cowan J.A. Glutathione complexed Fe-S centers. J. Am. Chem. Soc. 2012;134:10745–10748. doi: 10.1021/ja302186j. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Netz D.J., Stith C.M., Stumpfig M., Kopf G., Vogel D., Genau H.M., Stodola J.L., Lill R., Burgers P.M., Pierik A.J. Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes. Nat. Chem. Biol. 2011;8:125–132. doi: 10.1038/nchembio.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Rudolf J., Makrantoni V., Ingledew W.J., Stark M.J., White M.F. The DNA repair helicases XPD and FancJ have essential iron-sulfur domains. Mol. Cell. 2006;23:801–808. doi: 10.1016/j.molcel.2006.07.019. [DOI] [PubMed] [Google Scholar]
- 48.Kispal G., Sipos K., Lange H., Fekete Z., Bedekovics T., Janaky T., Bassler J., Aguilar Netz D.J., Balk J., Rotte C., et al. Biogenesis of cytosolic ribosomes requires the essential iron-sulphur protein Rli1p and mitochondria. EMBO J. 2005;24:589–598. doi: 10.1038/sj.emboj.7600541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Maio N., Rouault T.A. Iron-Sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery. Biochim. Biophys. Acta. 2015;1853:1493–1512. doi: 10.1016/j.bbamcr.2014.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wachnowsky C., Fidai I., Cowan J.A. Cytosolic iron-sulfur cluster transfer-a proposed kinetic pathway for reconstitution of glutaredoxin 3. FEBS Lett. 2016;590:4531–4540. doi: 10.1002/1873-3468.12491. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Muhlenhoff U., Molik S., Godoy J.R., Uzarska M.A., Richter N., Seubert A., Zhang Y., Stubbe J., Pierrel F., Herrero E., et al. Cytosolic monothiol glutaredoxins function in intracellular iron sensing and trafficking via their bound iron-sulfur cluster. Cell Metab. 2010;12:373–385. doi: 10.1016/j.cmet.2010.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Iwema T., Picciocchi A., Traore D.A., Ferrer J.L., Chauvat F., Jacquamet L. Structural basis for delivery of the intact [Fe2S2] cluster by monothiol glutaredoxin. Biochemistry. 2009;48:6041–6043. doi: 10.1021/bi900440m. [DOI] [PubMed] [Google Scholar]
- 53.Sen S., Rao B., Wachnowsky C., Cowan J.A. Cluster exchange reactivity of [2Fe-2S] cluster-bridged complexes of BOLA3 with monothiol glutaredoxins. Met. Integr. Biometal Sci. 2018;10:1282–1290. doi: 10.1039/C8MT00128F. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Xia H., Li B., Zhang Z., Wang Q., Qiao T., Li K. Human glutaredoxin 3 can bind and effectively transfer [4Fe-4S] cluster to apo-iron regulatory protein 1. Biochem. Biophys. Res. Commun. 2015;465:620–624. doi: 10.1016/j.bbrc.2015.08.073. [DOI] [PubMed] [Google Scholar]
- 55.Li H., Mapolelo D.T., Dingra N.N., Naik S.G., Lees N.S., Hoffman B.M., Riggs-Gelasco P.J., Huynh B.H., Johnson M.K., Outten C.E. The yeast iron regulatory proteins Grx3/4 and Fra2 form heterodimeric complexes containing a [2Fe-2S] cluster with cysteinyl and histidyl ligation. Biochemistry. 2009;48:9569–9581. doi: 10.1021/bi901182w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Zhang L.Q., Cui H., Yu Y.B., Shi H.Q., Zhou Y., Liu M.J. MicroRNA-141-3p inhibits retinal neovascularization and retinal ganglion cell apoptosis in glaucoma mice through the inactivation of Docking protein 5-dependent mitogen-activated protein kinase signaling pathway. J. Cell. Physiol. 2019;234:8873–8887. doi: 10.1002/jcp.27549. [DOI] [PubMed] [Google Scholar]
- 57.Wu B., Teng H., Zhang L., Li H., Li J., Wang L., Li H. Interaction of hydrogen sulfide with oxygen sensing under hypoxia. Oxid. Med. Cell. Longev. 2015;2015:758678. doi: 10.1155/2015/758678. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Greco V., Spalloni A., Corasolla Carregari V., Pieroni L., Persichilli S., Mercuri N.B., Urbani A., Longone P. Proteomics and toxicity analysis of spinal-cord primary cultures upon hydrogen sulfide treatment. Antioxidants. 2018;7:87. doi: 10.3390/antiox7070087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Liu X., Pan L., Zhuo Y., Gong Q., Rose P., Zhu Y. Hypoxia-Inducible factor-1alpha is involved in the pro-angiogenic effect of hydrogen sulfide under hypoxic stress. Biol. Pharm. Bull. 2010;33:1550–1554. doi: 10.1248/bpb.33.1550. [DOI] [PubMed] [Google Scholar]
- 60.Kai S., Tanaka T., Daijo H., Harada H., Kishimoto S., Suzuki K., Takabuchi S., Takenaga K., Fukuda K., Hirota K. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner. Antioxid. Redox Signal. 2012;16:203–216. doi: 10.1089/ars.2011.3882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Xu J., Li J., Yu Z., Rao H., Wang S., Lan H. HMGB1 promotes HLF-1 proliferation and ECM production through activating HIF1-alpha-regulated aerobic glycolysis. Pulm. Pharmacol. Ther. 2017;45:136–141. doi: 10.1016/j.pupt.2017.05.015. [DOI] [PubMed] [Google Scholar]
- 62.Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–185. doi: 10.1016/j.cmet.2006.02.002. [DOI] [PubMed] [Google Scholar]
- 63.Rak M., Rustin P. Supernumerary subunits NDUFA3, NDUFA5 and NDUFA12 are required for the formation of the extramembrane arm of human mitochondrial complex I. FEBS Lett. 2014;588:1832–1838. doi: 10.1016/j.febslet.2014.03.046. [DOI] [PubMed] [Google Scholar]
- 64.Peralta S., Torraco A., Wenz T., Garcia S., Diaz F., Moraes C.T. Partial complex I deficiency due to the CNS conditional ablation of Ndufa5 results in a mild chronic encephalopathy but no increase in oxidative damage. Hum. Mol. Genet. 2014;23:1399–1412. doi: 10.1093/hmg/ddt526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Nie H., Yu X., He H., Zhou L., Li Q., Song C., Wang D., Ren T., Chen Z., Huang H., et al. Hepatocyte miR-33a mediates mitochondrial dysfunction and hepatosteatosis by suppressing NDUFA5. J. Cell. Mol. Med. 2018;22:6285–6293. doi: 10.1111/jcmm.13918. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Liu Y., Fiskum G., Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 2002;80:780–787. doi: 10.1046/j.0022-3042.2002.00744.x. [DOI] [PubMed] [Google Scholar]
- 67.Kudin A.P., Bimpong-Buta N.Y., Vielhaber S., Elger C.E., Kunz W.S. Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem. 2004;279:4127–4135. doi: 10.1074/jbc.M310341200. [DOI] [PubMed] [Google Scholar]
- 68.Flones I.H., Fernandez-Vizarra E., Lykouri M., Brakedal B., Skeie G.O., Miletic H., Lilleng P.K., Alves G., Tysnes O.B., Haugarvoll K., et al. Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathol. 2018;135:409–425. doi: 10.1007/s00401-017-1794-7. [DOI] [PubMed] [Google Scholar]
- 69.Burwell L.S., Brookes P.S. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid. Redox Signal. 2008;10:579–599. doi: 10.1089/ars.2007.1845. [DOI] [PubMed] [Google Scholar]
- 70.Bordt E.A., Clerc P., Roelofs B.A., Saladino A.J., Tretter L., Adam-Vizi V., Cherok E., Khalil A., Yadava N., Ge S.X., et al. The Putative Drp1 Inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev. Cell. 2017;40:583–594. doi: 10.1016/j.devcel.2017.02.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3:187–197. doi: 10.1016/j.cmet.2006.01.012. [DOI] [PubMed] [Google Scholar]
- 72.Gasior M., Rogawski M.A., Hartman A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 2006;17:431–439. doi: 10.1097/00008877-200609000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Van der Auwera I., Wera S., Van Leuven F., Henderson S.T. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr. Metab. 2005;2:28. doi: 10.1186/1743-7075-2-28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., Morgan D.G., Morgan T.E., Finch C.E. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging. 2005;26:995–1000. doi: 10.1016/j.neurobiolaging.2004.09.014. [DOI] [PubMed] [Google Scholar]
- 75.Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N., Jr., Frautschy S.A., Cole G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. Off. J. Soc. Neurosci. 2005;25:3032–3040. doi: 10.1523/JNEUROSCI.4225-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Holmer H.K., Keyghobadi M., Moore C., Menashe R.A., Meshul C.K. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Synapse. 2005;57:100–112. doi: 10.1002/syn.20163. [DOI] [PubMed] [Google Scholar]
- 77.Tieu K., Perier C., Caspersen C., Teismann P., Wu D.C., Yan S.D., Naini A., Vila M., Jackson-Lewis V., Ramasamy R., et al. D-Beta-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Investig. 2003;112:892–901. doi: 10.1172/JCI200318797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Prins M.L., Fujima L.S., Hovda D.A. Age-Dependent reduction of cortical contusion volume by ketones after traumatic brain injury. J. Neurosci. Res. 2005;82:413–420. doi: 10.1002/jnr.20633. [DOI] [PubMed] [Google Scholar]
- 79.Cahill G.F., Jr., Veech R.L. Ketoacids? Good medicine? Trans. Am. Clin. Climatol. Assoc. 2003;114 [PMC free article] [PubMed] [Google Scholar]
- 80.Kashiwaya Y., Sato K., Tsuchiya N., Thomas S., Fell D.A., Veech R.L., Passonneau J.V. Control of glucose utilization in working perfused rat heart. J. Biol. Chem. 1994;269:25502–25514. [PubMed] [Google Scholar]
- 81.Sato K., Kashiwaya Y., Keon C.A., Tsuchiya N., King M.T., Radda G.K., Chance B., Clarke K., Veech R.L. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 1995;9:651–658. doi: 10.1096/fasebj.9.8.7768357. [DOI] [PubMed] [Google Scholar]
- 82.Wolf S., Arend O., Sponsel W.E., Schulte K., Cantor L.B., Reim M. Retinal hemodynamics using scanning laser ophthalmoscopy and hemorheology in chronic open-angle glaucoma. Ophthalmology. 1993;100:1561–1566. doi: 10.1016/S0161-6420(93)31444-2. [DOI] [PubMed] [Google Scholar]
- 83.Harju M., Vesti E. Blood flow of the optic nerve head and peripapillary retina in exfoliation syndrome with unilateral glaucoma or ocular hypertension. Graefe’s Arch. Clin. Exp. Ophthalmol. 2001;239:271–277. doi: 10.1007/s004170100269. [DOI] [PubMed] [Google Scholar]
- 84.Yin Z.Q., Vaegan, Millar T.J., Beaumont P., Sarks S. Widespread choroidal insufficiency in primary open-angle glaucoma. J. Glaucoma. 1997;6:23–32. doi: 10.1097/00061198-199702000-00006. [DOI] [PubMed] [Google Scholar]
- 85.Flammer J., Mozaffarieh M. Autoregulation, a balancing act between supply and demand. Can. J. Ophthalmol. 2008;43:317–321. doi: 10.3129/i08-056. [DOI] [PubMed] [Google Scholar]
- 86.Galassi F., Giambene B., Varriale R. Systemic vascular dysregulation and retrobulbar hemodynamics in normal-tension glaucoma. Investig. Ophthalmol. Vis. Sci. 2011;52:4467–4471. doi: 10.1167/iovs.10-6710. [DOI] [PubMed] [Google Scholar]
- 87.Zhao W., Wang R. H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am. J. Physiol. Heart Circ. Physiol. 2002;283:H474–H480. doi: 10.1152/ajpheart.00013.2002. [DOI] [PubMed] [Google Scholar]
- 88.Siragusa M., Fleming I. The eNOS signalosome and its link to endothelial dysfunction. Pflug. Arch. Eur. J. Physiol. 2016;468:1125–1137. doi: 10.1007/s00424-016-1839-0. [DOI] [PubMed] [Google Scholar]
- 89.Sessa W.C. eNOS at a glance. J. Cell Sci. 2004;117:2427–2429. doi: 10.1242/jcs.01165. [DOI] [PubMed] [Google Scholar]
- 90.Tasken K., Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 2004;84:137–167. doi: 10.1152/physrev.00021.2003. [DOI] [PubMed] [Google Scholar]
- 91.Aslam M., Hartel F.V., Arshad M., Gunduz D., Abdallah Y., Sauer H., Piper H.M., Noll T. cAMP/PKA antagonizes thrombin-induced inactivation of endothelial myosin light chain phosphatase: Role of CPI-17. Cardiovasc. Res. 2010;87:375–384. doi: 10.1093/cvr/cvq065. [DOI] [PubMed] [Google Scholar]
- 92.Collins C., Osborne L.D., Guilluy C., Chen Z., O’Brien E.T., 3rd, Reader J.S., Burridge K., Superfine R., Tzima E. Haemodynamic and extracellular matrix cues regulate the mechanical phenotype and stiffness of aortic endothelial cells. Nat. Commun. 2014;5:3984. doi: 10.1038/ncomms4984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Goldfinger L.E., Tzima E., Stockton R., Kiosses W.B., Kinbara K., Tkachenko E., Gutierrez E., Groisman A., Nguyen P., Chien S., et al. Localized alpha4 integrin phosphorylation directs shear stress-induced endothelial cell alignment. Circ. Res. 2008;103:177–185. doi: 10.1161/CIRCRESAHA.108.176354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Bakre M.M., Zhu Y., Yin H., Burton D.W., Terkeltaub R., Deftos L.J., Varner J.A. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat. Med. 2002;8:995–1003. doi: 10.1038/nm753. [DOI] [PubMed] [Google Scholar]
- 95.Jin H., Garmy-Susini B., Avraamides C.J., Stoletov K., Klemke R.L., Varner J.A. A PKA-Csk-pp60Src signaling pathway regulates the switch between endothelial cell invasion and cell-cell adhesion during vascular sprouting. Blood. 2010;116:5773–5783. doi: 10.1182/blood-2010-07-296210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Plitzko B., Havemeyer A., Bork B., Bittner F., Mendel R., Clement B. Defining the role of the NADH-Cytochrome-b5 Reductase 3 in the mitochondrial amidoxime reducing component enzyme system. Drug Metab. Dispos. Biol. Fate Chem. 2016;44:1617–1621. doi: 10.1124/dmd.116.071845. [DOI] [PubMed] [Google Scholar]
- 97.Wood K.C., Durgin B.G., Schmidt H.M., Hahn S.A., Baust J.J., Bachman T., Vitturi D.A., Ghosh S., Ofori-Acquah S.F., Mora A.L., et al. Smooth muscle cytochrome b5 reductase 3 deficiency accelerates pulmonary hypertension development in sickle cell mice. Blood Adv. 2019;3:4104–4116. doi: 10.1182/bloodadvances.2019000621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Rahaman M.M., Nguyen A.T., Miller M.P., Hahn S.A., Sparacino-Watkins C., Jobbagy S., Carew N.T., Cantu-Medellin N., Wood K.C., Baty C.J., et al. Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling. Circ. Res. 2017;121:137–148. doi: 10.1161/CIRCRESAHA.117.310705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Fukuto J.M., Carrington S.J., Tantillo D.J., Harrison J.G., Ignarro L.J., Freeman B.A., Chen A., Wink D.A. Small molecule signaling agents: The integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species. Chem. Res. Toxicol. 2012;25:769–793. doi: 10.1021/tx2005234. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Samaan S., Tranchevent L.C., Dardenne E., Polay Espinoza M., Zonta E., Germann S., Gratadou L., Dutertre M., Auboeuf D. The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways. Nucleic Acids Res. 2014;42:2197–2207. doi: 10.1093/nar/gkt1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Dewundara S.S., Wiggs J.L., Sullivan D.A., Pasquale L.R. Is estrogen a therapeutic target for glaucoma? Semin. Ophthalmol. 2016;31:140–146. doi: 10.3109/08820538.2015.1114845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Patel P., Harris A., Toris C., Tobe L., Lang M., Belamkar A., Ng A., Verticchio Vercellin A.C., Mathew S., Siesky B. Effects of sex hormones on ocular blood flow and intraocular pressure in primary open-angle glaucoma: A review. J. Glaucoma. 2018;27:1037–1041. doi: 10.1097/IJG.0000000000001106. [DOI] [PubMed] [Google Scholar]
- 103.Wickham L.A., Gao J., Toda I., Rocha E.M., Ono M., Sullivan D.A. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol. Scand. 2000;78:146–153. doi: 10.1034/j.1600-0420.2000.078002146.x. [DOI] [PubMed] [Google Scholar]
- 104.Kobayashi K., Kobayashi H., Ueda M., Honda Y. Estrogen receptor expression in bovine and rat retinas. Investig. Ophthalmol. Vis. Sci. 1998;39:2105–2110. [PubMed] [Google Scholar]
- 105.Chakrabarti M., Haque A., Banik N.L., Nagarkatti P., Nagarkatti M., Ray S.K. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res. Bull. 2014;109:22–31. doi: 10.1016/j.brainresbull.2014.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Jiang M., Ma X., Zhao Q., Li Y., Xing Y., Deng Q., Shen Y. The neuroprotective effects of novel estrogen receptor GPER1 in mouse retinal ganglion cell degeneration. Exp. Eye Res. 2019;189:107826. doi: 10.1016/j.exer.2019.107826. [DOI] [PubMed] [Google Scholar]
- 107.Sarzi E., Seveno M., Angebault C., Milea D., Ronnback C., Quiles M., Adrian M., Grenier J., Caignard A., Lacroux A., et al. Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy. Hum. Mol. Genet. 2016;25:2539–2551. doi: 10.1093/hmg/ddx376. [DOI] [PubMed] [Google Scholar]
- 108.Pisano A., Preziuso C., Iommarini L., Perli E., Grazioli P., Campese A.F., Maresca A., Montopoli M., Masuelli L., Sadun A.A., et al. Targeting estrogen receptor beta as preventive therapeutic strategy for Leber’s hereditary optic neuropathy. Hum. Mol. Genet. 2015;24:6921–6931. doi: 10.1093/hmg/ddv396. [DOI] [PubMed] [Google Scholar]
- 109.Chen X., Liu Y., Zhang Y., Kam W.R., Pasquale L.R., Sullivan D.A. Impact of aromatase absence on murine intraocular pressure and retinal ganglion cells. Sci. Rep. 2018;8:3280. doi: 10.1038/s41598-018-21475-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Feola A.J., Fu J., Allen R., Yang V., Campbell I.C., Ottensmeyer A., Ethier C.R., Pardue M. Menopause exacerbates visual dysfunction in experimental glaucoma. Exp. Eye Res. 2019;186:107706. doi: 10.1016/j.exer.2019.107706. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Shah A., Schiffmacher A.T., Taneyhill L.A. Annexin A6 controls neuronal membrane dynamics throughout chick cranial sensory gangliogenesis. Dev. Biol. 2017;425:85–99. doi: 10.1016/j.ydbio.2017.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Klee C.B. Ca2+-dependent phospholipid- (and membrane-) binding proteins. Biochemistry. 1988;27:6645–6653. doi: 10.1021/bi00418a001. [DOI] [PubMed] [Google Scholar]
- 113.Kapustin A.N., Shanahan C.M. Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J. Physiol. 2016;594:2905–2914. doi: 10.1113/JP271340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Hubner C.A., Schroeder B.C., Ehmke H. Regulation of vascular tone and arterial blood pressure: Role of chloride transport in vascular smooth muscle. Pflug. Arch. Eur. J. Physiol. 2015;467:605–614. doi: 10.1007/s00424-014-1684-y. [DOI] [PubMed] [Google Scholar]
- 115.Ye S., Chang Y., Kim C.W., Kwon M.J., Choi Y., Ahn J., Kim J.M., Kim H.S., Shin H., Ryu S. Intraocular pressure and coronary artery calcification in asymptomatic men and women. Br. J. Ophthalmol. 2015;99:932–936. doi: 10.1136/bjophthalmol-2014-305925. [DOI] [PubMed] [Google Scholar]
- 116.Borden L.A. GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochem. Int. 1996;29:335–356. doi: 10.1016/0197-0186(95)00158-1. [DOI] [PubMed] [Google Scholar]
- 117.Crooks J., Kolb H. Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina. J. Comp. Neurol. 1992;315:287–302. doi: 10.1002/cne.903150305. [DOI] [PubMed] [Google Scholar]
- 118.Hilton E.J., Hosking S.L., Betts T. The effect of antiepileptic drugs on visual performance. Seizure. 2004;13:113–128. doi: 10.1016/S1059-1311(03)00082-7. [DOI] [PubMed] [Google Scholar]
- 119.Sakaew W., Tachow A., Thoungseabyoun W., Khrongyut S., Rawangwong A., Polsan Y., Masahiko W., Kondo H., Hipkaeo W. Expression and localization of VIAAT in distal uriniferous tubular epithelium of mouse. Ann. Anat. Anat. Anz. 2019;222:21–27. doi: 10.1016/j.aanat.2018.11.002. [DOI] [PubMed] [Google Scholar]
- 120.Kononenko N.L., Puchkov D., Classen G.A., Walter A.M., Pechstein A., Sawade L., Kaempf N., Trimbuch T., Lorenz D., Rosenmund C., et al. Clathrin/AP-2 mediate synaptic vesicle reformation from endosome-like vacuoles but are not essential for membrane retrieval at central synapses. Neuron. 2014;82:981–988. doi: 10.1016/j.neuron.2014.05.007. [DOI] [PubMed] [Google Scholar]
- 121.Kononenko N.L., Classen G.A., Kuijpers M., Puchkov D., Maritzen T., Tempes A., Malik A.R., Skalecka A., Bera S., Jaworski J., et al. Retrograde transport of TrkB-containing autophagosomes via the adaptor AP-2 mediates neuronal complexity and prevents neurodegeneration. Nat. Commun. 2017;8:14819. doi: 10.1038/ncomms14819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Helbig I., Lopez-Hernandez T., Shor O., Galer P., Ganesan S., Pendziwiat M., Rademacher A., Ellis C.A., Humpfer N., Schwarz N., et al. A recurrent missense variant in AP2M1 impairs clathrin-mediated endocytosis and causes developmental and epileptic encephalopathy. Am. J. Hum. Genet. 2019;104:1060–1072. doi: 10.1016/j.ajhg.2019.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Kittler J.T., Chen G., Honing S., Bogdanov Y., McAinsh K., Arancibia-Carcamo I.L., Jovanovic J.N., Pangalos M.N., Haucke V., Yan Z., et al. Phospho-dependent binding of the clathrin AP2 adaptor complex to GABAA receptors regulates the efficacy of inhibitory synaptic transmission. Proc. Natl. Acad. Sci. USA. 2005;102:14871–14876. doi: 10.1073/pnas.0506653102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Froemke R.C. Plasticity of cortical excitatory-inhibitory balance. Annu. Rev. Neurosci. 2015;38:195–219. doi: 10.1146/annurev-neuro-071714-034002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Smith K.R., Muir J., Rao Y., Browarski M., Gruenig M.C., Sheehan D.F., Haucke V., Kittler J.T. Stabilization of GABA(A) receptors at endocytic zones is mediated by an AP2 binding motif within the GABA(A) receptor beta3 subunit. J. Neurosci. Off. J. Soc. Neurosci. 2012;32:2485–2498. doi: 10.1523/JNEUROSCI.1622-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Neal M.J., Shah M.A. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br. J. Pharmacol. 1990;100:324–328. doi: 10.1111/j.1476-5381.1990.tb15803.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Hosking S.L., Hilton E.J. Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: Ocular perfusion and visual performance. Ophthalmic Physiol. Opt. J. Br. Coll. Ophthalmic Opt. 2002;22:440–447. doi: 10.1046/j.1475-1313.2002.00063.x. [DOI] [PubMed] [Google Scholar]
- 128.Hilton E.J., Hosking S.L., Betts T. Epilepsy patients treated with antiepileptic drug therapy exhibit compromised ocular perfusion characteristics. Epilepsia. 2002;43:1346–1350. doi: 10.1046/j.1528-1157.2002.44901.x. [DOI] [PubMed] [Google Scholar]
- 129.Hammond E.J., Wilder B.J. Gamma-vinyl GABA. Gen. Pharmacol. 1985;16:441–447. doi: 10.1016/0306-3623(85)90002-3. [DOI] [PubMed] [Google Scholar]
- 130.Wild J.M., Martinez C., Reinshagen G., Harding G.F. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 1999;40:1784–1794. doi: 10.1111/j.1528-1157.1999.tb01599.x. [DOI] [PubMed] [Google Scholar]
- 131.Fujiwara M., Muramatsu I. Gamma-Aminobutyric acid receptor on vascular smooth muscle of dog cerebral arteries. Br. J. Pharmacol. 1975;55:561–562. doi: 10.1111/j.1476-5381.1975.tb07434.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Edvinsson L., Krause D.N. Pharmacological characterization of GABA receptors mediating vasodilation of verebral arteries in vitro. Brain Res. 1979;173:89–97. doi: 10.1016/0006-8993(79)91098-9. [DOI] [PubMed] [Google Scholar]
- 133.Hinds K., Monaghan K.P., Frolund B., McGeown J.G., Curtis T.M. GABAergic control of arteriolar diameter in the rat retina. Investig. Ophthalmol. Vis. Sci. 2013;54:6798–6805. doi: 10.1167/iovs.13-12362. [DOI] [PubMed] [Google Scholar]
- 134.Deng X.W., Dubiel W., Wei N., Hofmann K., Mundt K., Colicelli J., Kato J., Naumann M., Segal D., Seeger M., et al. Unified nomenclature for the COP9 signalosome and its subunits: An essential regulator of development. Trends Genet. TIG. 2000;16:202–203. doi: 10.1016/S0168-9525(00)01982-X. [DOI] [PubMed] [Google Scholar]
- 135.Boussiotis V.A., Freeman G.J., Taylor P.A., Berezovskaya A., Grass I., Blazar B.R., Nadler L.M. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 2000;6:290–297. doi: 10.1038/73144. [DOI] [PubMed] [Google Scholar]
- 136.Doronkin S., Djagaeva I., Beckendorf S.K. The COP9 signalosome promotes degradation of Cyclin E during early Drosophila oogenesis. Dev. Cell. 2003;4:699–710. doi: 10.1016/S1534-5807(03)00121-7. [DOI] [PubMed] [Google Scholar]
- 137.Yan J., Walz K., Nakamura H., Carattini-Rivera S., Zhao Q., Vogel H., Wei N., Justice M.J., Bradley A., Lupski J.R. COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast. Mol. Cell. Biol. 2003;23:6798–6808. doi: 10.1128/MCB.23.19.6798-6808.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Hetfeld B.K., Peth A., Sun X.M., Henklein P., Cohen G.M., Dubiel W. The COP9 signalosome-mediated deneddylation is stimulated by caspases during apoptosis. Apoptosis Int. J. Program. Cell Death. 2008;13:187–195. doi: 10.1007/s10495-007-0164-7. [DOI] [PubMed] [Google Scholar]
- 139.Da Silva Correia J., Miranda Y., Leonard N., Ulevitch R.J. The subunit CSN6 of the COP9 signalosome is cleaved during apoptosis. J. Biol. Chem. 2007;282:12557–12565. doi: 10.1074/jbc.M609587200. [DOI] [PubMed] [Google Scholar]
- 140.De Laat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768–785. doi: 10.1101/gad.13.7.768. [DOI] [PubMed] [Google Scholar]
- 141.Scharer O.D. Nucleotide excision repair in eukaryotes. Cold Spring Harb. Perspect. Biol. 2013;5:a012609. doi: 10.1101/cshperspect.a012609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Zhang M., Du W., Acklin S.M., Jin S., Xia F. SIRT2 protects peripheral neurons from cisplatin-induced injury by enhancing nucleotide excision repair. J. Clin. Investig. 2020 doi: 10.1172/JCI123159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Barros L.F., San Martin A., Ruminot I., Sandoval P.Y., Fernandez-Moncada I., Baeza-Lehnert F., Arce-Molina R., Contreras-Baeza Y., Cortes-Molina F., Galaz A., et al. Near-critical GLUT1 and Neurodegeneration. J. Neurosci. Res. 2017;95:2267–2274. doi: 10.1002/jnr.23998. [DOI] [PubMed] [Google Scholar]
- 144.Perumal N., Funke S., Pfeiffer N., Grus F.H. Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients. Sci. Rep. 2016;6:29629. doi: 10.1038/srep29629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Perumal N., Funke S., Pfeiffer N., Grus F.H. Characterization of lacrimal proline-rich protein 4 (PRR4) in human tear proteome. Proteomics. 2014;14:1698–1709. doi: 10.1002/pmic.201300039. [DOI] [PubMed] [Google Scholar]
- 146.Flammer J., Orgul S., Costa V.P., Orzalesi N., Krieglstein G.K., Serra L.M., Renard J.P., Stefansson E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 2002;21:359–393. doi: 10.1016/S1350-9462(02)00008-3. [DOI] [PubMed] [Google Scholar]
- 147.Osborne N.N., Melena J., Chidlow G., Wood J.P. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: Possible implication for the treatment of glaucoma. Br. J. Ophthalmol. 2001;85:1252–1259. doi: 10.1136/bjo.85.10.1252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Golubnitschaja-Labudova O., Liu R., Decker C., Zhu P., Haefliger I.O., Flammer J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr. Eye Res. 2000;21:867–876. doi: 10.1076/ceyr.21.5.867.5534. [DOI] [PubMed] [Google Scholar]
- 149.Flammer J. Glaucomatous optic neuropathy: A reperfusion injury. Klin. Mon. Fur Augenheilkd. 2001;218:290–291. doi: 10.1055/s-2001-15883. [DOI] [PubMed] [Google Scholar]
- 150.Berkowitz B.A., Lukaszew R.A., Mullins C.M., Penn J.S. Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Investig. Ophthalmol. Vis. Sci. 1998;39:391–396. [PubMed] [Google Scholar]
- 151.Nadal-Nicolas F.M., Jimenez-Lopez M., Sobrado-Calvo P., Nieto-Lopez L., Canovas-Martinez I., Salinas-Navarro M., Vidal-Sanz M., Agudo M. Brn3a as a marker of retinal ganglion cells: Qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Investig. Ophthalmol. Vis. Sci. 2009;50:3860–3868. doi: 10.1167/iovs.08-3267. [DOI] [PubMed] [Google Scholar]
- 152.Nadal-Nicolas F.M., Sobrado-Calvo P., Jimenez-Lopez M., Vidal-Sanz M., Agudo-Barriuso M. Long-Term effect of optic nerve axotomy on the retinal ganglion cell layer. Investig. Ophthalmol. Vis. Sci. 2015;56:6095–6112. doi: 10.1167/iovs.15-17195. [DOI] [PubMed] [Google Scholar]
- 153.Nadal-Nicolas F.M., Salinas-Navarro M., Jimenez-Lopez M., Sobrado-Calvo P., Villegas-Perez M.P., Vidal-Sanz M., Agudo-Barriuso M. Displaced retinal ganglion cells in albino and pigmented rats. Front. Neuroanat. 2014;8:99. doi: 10.3389/fnana.2014.00099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154.Anders F., Teister J., Liu A., Funke S., Grus F.H., Thanos S., von Pein H.D., Pfeiffer N., Prokosch V. Intravitreal injection of beta-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma. PLoS ONE. 2017;12:e0175451. doi: 10.1371/journal.pone.0175451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155.Manicam C., Perumal N., Pfeiffer N., Grus F.H., Gericke A. First insight into the proteome landscape of the porcine short posterior ciliary arteries: Key signalling pathways maintaining physiologic functions. Sci. Rep. 2016;6:38298. doi: 10.1038/srep38298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156.Manicam C., Perumal N., Wasielica-Poslednik J., Ngongkole Y.C., Tschabunin A., Sievers M., Lisch W., Pfeiffer N., Grus F.H., Gericke A. Proteomics unravels the regulatory mechanisms in human tears following acute renouncement of contact lens use: A comparison between hard and soft lenses. Sci. Rep. 2018;8:11526. doi: 10.1038/s41598-018-30032-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.